Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (1416)	11/29/2006 8:26:44 PM
From: JMarcus	Read Replies (1) \| Respond to of 1494

It will be interesting to see what spin Paul Freiman puts on this analysis of the data from the failed European trial conducted by Knoll. I'll be attending the December 18th stockholders meeting and I'll be sure to ask him. I suspect that NTII has had better access to the Knoll data than the investigators had. The investigators did complain that after Knoll was sold <<the data from the study were not fully available to the investigators, making further analysis difficult.>> The dosing regimen in NTII's current trials is very different from that in the failed European trial. Paul describes the difference thus: <<Rather than infusing the drug for five days, as Knoll did, we are providing a one-day infusion, at a dose that we feel will provide the optimal effect/side effect ratio.>> So lack of efficacy in the 4-6 hour window using one dosing regimen wouldn't mean that a different dosing regimen would also fail in that same 4-6 hour window. But having said that, I don't recall what the data were that give NTII an expectation of showing some efficacy in the 4-6 hour window. Marc